Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
8.91
-0.18 (-1.98%)
At close: Nov 20, 2025, 4:00 PM EST
8.86
-0.05 (-0.54%)
After-hours: Nov 20, 2025, 5:27 PM EST

Lexeo Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
---0.651.660.52
Revenue Growth (YoY)
----60.53%219.59%-
Cost of Revenue
65.9574.0953.1349.1645.124.32
Gross Profit
-65.95-74.09-53.13-48.51-43.46-3.8
Selling, General & Admin
47.5731.6815.38127.170.79
Operating Expenses
47.5731.6815.38127.170.79
Operating Income
-113.52-105.77-68.51-60.51-50.64-4.59
Interest Expense
-0.11-0.14-0.21-0.09--0.15
Interest & Investment Income
5.387.562.871.330.02-
Other Non Operating Income (Expenses)
-0.03-0.01-0.54-0-0
EBT Excluding Unusual Items
-108.27-98.36-66.39-59.28-50.62-4.73
Gain (Loss) on Sale of Investments
3.310.02----
Other Unusual Items
------0.42
Pretax Income
-104.97-98.33-66.39-59.28-50.62-5.15
Net Income
-104.97-98.33-66.39-59.28-50.62-5.15
Net Income to Common
-104.97-98.33-66.39-59.28-50.62-5.15
Shares Outstanding (Basic)
43325221
Shares Outstanding (Diluted)
43325221
Shares Change (YoY)
54.63%493.67%228.42%5.00%7.72%-
EPS (Basic)
-2.45-3.09-12.40-36.36-32.60-3.57
EPS (Diluted)
-2.45-3.09-12.40-36.36-32.60-3.57
Free Cash Flow
-107.21-81.63-59.61-55.23-44.37-3.13
Free Cash Flow Per Share
-2.51-2.57-11.13-33.88-28.58-2.17
Operating Margin
----9252.14%-3055.94%-884.86%
Profit Margin
----9063.76%-3055.04%-993.83%
Free Cash Flow Margin
----8445.26%-2677.73%-604.35%
EBITDA
-112.93-105.14-67.94-60.24-50.62-
D&A For EBITDA
0.590.630.580.270.01-
EBIT
-113.52-105.77-68.51-60.51-50.64-4.59
Revenue as Reported
---0.651.660.52
Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q